CompaniesAdaptive Biotechnologies
Adaptive Biotechnologies logo

Adaptive Biotechnologies

active
Seattle, WA, United States
Founded 2009
Website
About

T Cell Receptor Analysis

Areas of Focus

Categories

Non-PharmaceuticalSeattle/Pacific Northwest
Team (12)
Chad Robins
Chad Robins
Chad Robins
Adaptive Biotechnologies
team_member
Francis Lo
Francis Lo
Francis Lo
Adaptive Biotechnologies
team_member
Harlan Robins
Harlan Robins
Harlan Robins, PhD
Adaptive Biotechnologies
team_member
Julie Rubinstein
Julie Rubinstein
Julie Rubinstein
Adaptive Biotechnologies
team_member
Katey Owen
Katey Owen
Katey Owen, PhD
Adaptive Biotechnologies
team_member
Kyle Piskel
Kyle Piskel
Kyle Piskel
Adaptive Biotechnologies
team_member
View all 12 team members →
Clinical Trials (15)
View all

Total Trials

15

As Lead Sponsor

8

As Collaborator

7

Total Enrollment

3,757

By Phase

PHASE2: 5

By Status

COMPLETED: 6RECRUITING: 4TERMINATED: 2NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
NCT02553642
NCT04419519
NCT04545333
NCT05271630
NCT05255354
NCT06252675
NCT06828991
Hover over trial bars to see details

Recent Trials

NCT06828991Collaborator
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
PHASE2Recruiting
40 participants
Started: Sep 4, 2025 · Completed: Apr 30, 2030
NCT06557330Collaborator
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
PHASE2Not yet recruiting
24 participants
Started: Jun 30, 2025 · Completed: Mar 30, 2028
NCT06252675Collaborator
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
PHASE2Recruiting
30 participants
Started: Jun 11, 2024 · Completed: Jul 31, 2028
NCT05769829Lead Sponsor
ImmuneSense™ IBD Study
N/ATerminated
484 participants
Started: Oct 31, 2022 · Completed: Aug 14, 2023
NCT05255354Lead Sponsor
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
N/ARecruiting
300 participants
Started: Jun 1, 2022 · Completed: Dec 31, 2026
View all 15 trials →
Funding History (20)
8-K
Aug 18, 2025
Filing
8-K
Aug 5, 2025
Filing
8-K
Jun 12, 2025
Filing
8-K
May 1, 2025
Filing
DEFA14A
Apr 29, 2025
Filing
DEF 14A
Apr 29, 2025
Filing
8-K
Feb 11, 2025
Filing
8-K
Nov 7, 2024
Filing
8-K
Aug 1, 2024
Filing
8-K
Jun 11, 2024
Filing
Locations (1)
Headquarters
Seattle, WA, United States
Map

Loading map...